Shots:
STADA and Sino Biopharmaceutical, through its subsidiary CTTQ, have entered into a strategic biosimilar partnership designed to broaden patient access to biological medicines in key markets
As per the deal, CTTQ will develop, manufacture & supply the biosimilar candidates, while STADA will hold marketing authorizations and exclusive sales & marketing rights in the EU,…
